Home › Companies › Lexicon Pharmaceuticals, Inc. › 2025-2026
At Lexicon Pharmaceuticals, Inc.'s shareholder meeting held April 30, 2026, in the 2025-2026 proxy season, 79 asset managers reported how they voted in their SEC Form N-PX filings, covering 418 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Lexicon Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 30, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Lexicon Pharmaceuticals, Inc.’s Form 8-K, filed April 30, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of April 30, 2026: 8 items on Lexicon Pharmaceuticals, Inc.’s Form 8-K, filed April 30, 2026: 8 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Lexicon Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Lexicon Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 30, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Samuel L. Barker, Ph.D. | 297,300,686 | -- | -- | 5,122,476 | 44,263,056 | 98% | Not verified | — |
| Elect Director: Christopher J. Sobecki | 298,276,486 | -- | -- | 4,146,676 | 44,263,056 | 99% | Not verified | — |
| Elect Director: Judith L. Swain, M.D. | 297,407,977 | -- | -- | 5,015,185 | 44,263,056 | 98% | Not verified | — |
| 2. Ratification and approval of the Company's Seventh Amended and Restated Certificate of Incorporation | 297,742,443 | 4,445,276 | 235,443 | -- | 44,263,056 | 99% | Not verified | — |
| 3. Approval of the Company's 2026 Equity Incentive Plan | 294,995,982 | 7,116,668 | 310,512 | -- | 44,263,056 | 98% | Not verified | — |
| 4. Approval of the Company's 2026 Non-Employee Directors' Equity Incentive Plan | 294,908,842 | 7,112,300 | 402,020 | -- | 44,263,056 | 98% | Not verified | — |
| 5. Advisory vote to approve the compensation paid to the Company's named executive officers | 294,969,542 | 6,947,006 | 506,614 | -- | 44,263,056 | 98% | Not verified | — |
| 6. Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2026 | 344,266,630 | 2,225,211 | 194,377 | -- | -- | 99.3% | Not verified | — |
Source: Lexicon Pharmaceuticals, Inc., Form 8-K, filed with the SEC on April 30, 2026 — read the filing on EDGAR.
Each item below shows how the 79 asset managers that disclosed a Lexicon Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Lexicon Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Christopher J. Sobecki
Lexicon Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christopher J. Sobecki”): 298,276,486 for, 4,146,676 withheld, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 30,235,362 for, 13,577 withheld, 9 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,377,556 | 0 | 0 | 0 | For |
| Vanguard | 4,545,433 | 0 | 9 | 12,678 | For |
| Charles Schwab | 1,119,813 | 0 | 0 | 0 | For |
| Invesco | 134,299 | 0 | 0 | 0 | For |
| Goldman Sachs | 30,324 | 0 | 0 | 0 | For |
| Victory Capital | 20,065 | 0 | 0 | 0 | For |
| John Hancock | 6,264 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 899 | Withhold |
| Guggenheim | 408 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Judith L. Swain, M.D.
Lexicon Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Judith L. Swain, M.D.”): 297,407,977 for, 5,015,185 withheld, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 30,205,036 for, 43,901 withheld, 11 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,377,556 | 0 | 0 | 0 | For |
| Vanguard | 4,545,431 | 0 | 11 | 12,678 | For |
| Charles Schwab | 1,119,813 | 0 | 0 | 0 | For |
| Invesco | 134,299 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 30,324 | Withhold |
| Victory Capital | 20,065 | 0 | 0 | 0 | For |
| John Hancock | 6,264 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 899 | Withhold |
| Guggenheim | 408 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Samuel L. Barker, Ph.D.
Lexicon Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Samuel L. Barker, Ph.D.”): 297,300,686 for, 5,122,476 withheld, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 30,235,359 for, 13,577 withheld, 12 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,377,556 | 0 | 0 | 0 | For |
| Vanguard | 4,545,430 | 0 | 12 | 12,678 | For |
| Charles Schwab | 1,119,813 | 0 | 0 | 0 | For |
| Invesco | 134,299 | 0 | 0 | 0 | For |
| Goldman Sachs | 30,324 | 0 | 0 | 0 | For |
| Victory Capital | 20,065 | 0 | 0 | 0 | For |
| John Hancock | 6,264 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 899 | Withhold |
| Guggenheim | 408 | 0 | 0 | 0 | For |
99% Majority: yes · of votes cast
Description as filed by funds: RATIFICATION AND APPROVAL OF THE COMPANY'S SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Lexicon Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification and approval of the Company's Seventh Amended and Restated Certificate of Incorporation”): 297,742,443 for, 4,445,276 against, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 30,235,361 for, 13,586 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,377,556 | 0 | 0 | 0 | For |
| Vanguard | 4,545,432 | 12,687 | 0 | 0 | For |
| Charles Schwab | 1,119,813 | 0 | 0 | 0 | For |
| Invesco | 134,299 | 0 | 0 | 0 | For |
| Goldman Sachs | 30,324 | 0 | 0 | 0 | For |
| Victory Capital | 20,065 | 0 | 0 | 0 | For |
| John Hancock | 6,264 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 899 | 0 | 0 | Against |
| Guggenheim | 408 | 0 | 0 | 0 | For |
99.9% of fund votes cast · no official result
Description as filed by funds: APPROVAL OF THE COMPANY'S 2026 EQUITY INCENTIVE PLAN
The 11 asset managers below reported 30,236,355 for, 13,593 against, 1 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,377,556 | 0 | 0 | 0 | For |
| Vanguard | 4,545,426 | 12,694 | 1 | 0 | For |
| Charles Schwab | 1,119,813 | 0 | 0 | 0 | For |
| Invesco | 134,299 | 0 | 0 | 0 | For |
| Goldman Sachs | 30,324 | 0 | 0 | 0 | For |
| Victory Capital | 20,065 | 0 | 0 | 0 | For |
| John Hancock | 6,264 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,200 | 0 | 0 | 0 | For |
| MIDDLETON & CO INC/MA | 1,000 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 899 | 0 | 0 | Against |
| Guggenheim | 408 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99.9% of fund votes cast · no official result
Description as filed by funds: APPROVAL OF THE COMPANY'S 2026 NON-EMPLOYEE DIRECTORS' EQUITY INCENTIVE PLAN
The 11 asset managers below reported 30,249,932 for, 16 against, 1 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,377,556 | 0 | 0 | 0 | For |
| Vanguard | 4,558,104 | 16 | 1 | 0 | For |
| Charles Schwab | 1,119,813 | 0 | 0 | 0 | For |
| Invesco | 134,299 | 0 | 0 | 0 | For |
| Goldman Sachs | 30,324 | 0 | 0 | 0 | For |
| Victory Capital | 20,065 | 0 | 0 | 0 | For |
| John Hancock | 6,264 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,200 | 0 | 0 | 0 | For |
| MIDDLETON & CO INC/MA | 1,000 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 899 | 0 | 0 | 0 | For |
| Guggenheim | 408 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS
Lexicon Pharmaceuticals, Inc.’s own tally for this item (“5. Advisory vote to approve the compensation paid to the Company's named executive officers”): 294,969,542 for, 6,947,006 against, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,377,556 | 0 | 0 | 0 | For |
| Vanguard | 4,558,104 | 15 | 1 | 0 | For |
| Charles Schwab | 1,119,813 | 0 | 0 | 0 | For |
| Invesco | 134,299 | 0 | 0 | 0 | For |
| Goldman Sachs | 30,324 | 0 | 0 | 0 | For |
| Victory Capital | 20,065 | 0 | 0 | 0 | For |
| John Hancock | 6,264 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 899 | 0 | 0 | 0 | For |
| Guggenheim | 408 | 0 | 0 | 0 | For |
| FORUM FUNDS | 37 | 0 | 0 | 0 | For |
Fund voting reports, all 11 managers: 30,248,969 for, 15 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Artal Group S.A. | 154,734,327 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 44,303,518 | 0 | 0 | 0 | For |
| Fidelity | 43,441,179 | 0 | 0 | 0 | For |
| Sessa Capital IM, L.P. | 14,185,247 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,671,521 | 0 | 0 | 0 | For |
| Point72 | 2,284,216 | 0 | 0 | 0 | For |
| CIBC Private Wealth Group LLC | 1,800,000 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 1,175,510 | 0 | 0 | 0 | For |
| Charles Schwab | 1,120,078 | 0 | 0 | 0 | For |
| BBR PARTNERS, LLC | 680,000 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 644,587 | 0 | 0 | 0 | For |
| BlackRock | 532,740 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 519,458 | 0 | 0 | 0 | For |
| Citadel | 441,261 | 0 | 0 | 0 | For |
| Two Sigma | 431,370 | 0 | 0 | 0 | For |
| Goldman Sachs | 406,450 | 0 | 0 | 0 | For |
| State Street | 310,438 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 310,068 | 0 | 0 | 0 | For |
| Vanguard | 289,117 | 0 | 0 | 0 | For |
| Northern Trust | 239,776 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 231,000 | 0 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 223,679 | 0 | 0 | 0 | For |
| Invesco | 134,299 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 127,532 | 0 | 0 | 0 | For |
| AQR | 101,307 | 0 | 0 | 0 | For |
Institutional-manager reports, all 73 managers: 271,995,516 for, 2,089 against. Showing the 25 largest; every one is in the interactive database (link above).
99.3% Majority: yes · of votes cast
Description as filed by funds: RATIFICATION AND APPROVAL OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026
Lexicon Pharmaceuticals, Inc.’s own tally for this item (“6. Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2026”): 344,266,630 for, 2,225,211 against, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 30,242,104 for, 6,844 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,377,556 | 0 | 0 | 0 | For |
| Vanguard | 4,552,175 | 5,945 | 0 | 0 | For |
| Charles Schwab | 1,119,813 | 0 | 0 | 0 | For |
| Invesco | 134,299 | 0 | 0 | 0 | For |
| Goldman Sachs | 30,324 | 0 | 0 | 0 | For |
| Victory Capital | 20,065 | 0 | 0 | 0 | For |
| John Hancock | 6,264 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 899 | 0 | 0 | Against |
| Guggenheim | 408 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 423,680,611 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 5.75% |
| 2 | Vanguard | 1.08% |
| 3 | Charles Schwab | 0.26% |
| 4 | Invesco | 0.03% |
| 5 | Goldman Sachs | <0.01% |
| 6 | Victory Capital | <0.01% |
| 7 | John Hancock | <0.01% |
| 8 | Blackstone Alternative Investment Funds | <0.01% |
| 9 | Advisors' Inner Circle Fund III | <0.01% |
| 10 | Guggenheim | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Artal Group S.A. | 36.52% |
| 2 | Siren, L.L.C. | 10.46% |
| 3 | Fidelity | 10.25% |
| 4 | Sessa Capital IM, L.P. | 3.35% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.63% |
| 6 | Point72 | 0.54% |
| 7 | CIBC Private Wealth Group LLC | 0.42% |
| 8 | MARSHALL WACE, LLP | 0.28% |
| 9 | Charles Schwab | 0.26% |
| 10 | BBR PARTNERS, LLC | 0.16% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Invus, L.P. and related parties | — | DEF14A |
| Artal Participations S.a r.l. | — | 13D |
| FMR LLC | — | 13G |
| Raymond Debbane | — | DEF14A |
| FMR (Fidelity) | — | 13F |
| Vanguard Group | — | 13F |
| Point72 | — | 13F |
| Millennium Management | — | 13F |
| BlackRock | — | 13F |
| Geode Capital | — | 13F |
Percentages above are of 423,680,611 shares outstanding, as reported by Lexicon Pharmaceuticals, Inc. on its Form 10-K dated March 4, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Lexicon Pharmaceuticals, Inc.’s 10-K dated March 4, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Lexicon Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Lexicon Pharmaceuticals (LXRX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/lexicon-pharmaceuticals-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.